Summary
Eric Aboagye is Professor of Cancer Pharmacology & Molecular Imaging and Director of the CRUK-EPSRC-MRC-NIHR Comprehensive Cancer Imaging Centre. He joined the college after a PhD at the CRUK Beatson Laboratories in Glasgow, UK and post-doc fellowship at The Johns Hopkins University & Hospital in Baltimore, USA. His group is interested in the discovery and development of new methods for experimental and clinical cancer molecular imaging. In the past 5 years, the team has invented and translated three novel cancer diagnostics into human application. He has acted as an advisor to GE-Healthcare, GSK, Roche and Novartis.
Professor Aboagye was recipient of the 2009 Sir Mackenzie Davidson Medal and was elected as a Fellow of the Academy of Medical Sciences in 2010. Academy Fellows are elected for outstanding contributions to the advancement of medical science, for innovative application of scientific knowledge or for conspicuous service to healthcare.
Publications
Journals
Inglese M, Katherine L O, Lesley H, et al., 2019, Reliability of dynamic contrast enhanced magnetic resonance imaging data in primary brain tumours: a comparison of Tofts and shutter speed models, Neuroradiology, Vol:61, ISSN:0028-3940, Pages:1375-1386
Sharma R, Valls PO, Inglese M, et al., 2019, [18F]Fluciclatide PET as a biomarker of response to combination therapy of pazopanib and paclitaxel in platinum-resistant/refractory ovarian cancer, European Journal of Nuclear Medicine and Molecular Imaging, ISSN:0340-6997
Allott L, Barnes C, Brickute D, et al., 2019, Solid-supported cyanoborohydride cartridges for automation of reductive amination radiochemistry, Reaction Chemistry and Engineering, Vol:4, ISSN:2058-9883, Pages:1748-1751
Conference
Sharma R, Wang W, Yusuf S, et al., 2019, [Ga-68]-DOTATATE PET/CT parameters predict response to peptide receptor radionuclide therapy in neuroendocrine tumours, 32nd Annual Congress of the European-Association-of-Nuclear-Medicine (EANM), SPRINGER, Pages:S640-S640, ISSN:1619-7070
Sharma R, Valls PO, Inglese M, et al., 2019, [F-18]fluciclatide Pet As A Biomarker Of Response To Combination Therapy Of Pazopanib And Paclitaxel In Platinum-resistant/refractory Ovarian Cancer, 32nd Annual Congress of the European-Association-of-Nuclear-Medicine (EANM), SPRINGER, Pages:S223-S223, ISSN:1619-7070